Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kestra Medical Technologies (KMTS) announced publication of ACE-PAS results, showing its ASSURE wearable defibrillator met both primary safety and effectiveness endpoints.
The prospective post-approval study enrolled 21,612 patients across 35 U.S. states. ASSURE converted all 303 analyzable ventricular tachycardia or ventricular fibrillation (VT/VF) shock events with one or more shocks. The inappropriate-shock rate was 0.0065 per patient-month, beating the prespecified safety goal. Median daily wear was 23.1 hours; 94% of patients had no false-positive shock alarms.
VT/VF occurred in 2.6% of patients, with events continuing beyond the first month. Results appeared in the Journal of Cardiovascular Electrophysiology. Kestra projects that an enhanced detection algorithm introduced in April 2026 will reduce the inappropriate-shock rate by nearly 70%, to 0.0020 per patient-month.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointASSURE achieved 100% all-shock conversion across 303 analyzable VT/VF shock events, meeting the primary effectiveness endpoint.
- Major pointThe inappropriate-shock rate of 0.0065 per patient-month beat the prespecified safety goal, meeting the primary safety endpoint.
- Minor point94% of patients experienced no false-positive shock alarms.
- Minor pointMedian daily wear reached 23.1 hours; 30% continued beyond 90 days while maintaining that median.
- Minor point. Forward-looking: it has not happened yet and may not happen.Kestra projects its enhanced algorithm will reduce inappropriate shocks by nearly 70%, to 0.0020 per patient-month.
Negative
- None.
Key Figures
- Patients enrolled
- 21,612 patients
- ACE-PAS prospective real-world study
- All-shock conversion success
- 100%
- 303 analyzable VT/VF shock events; primary effectiveness endpoint
- Inappropriate-shock rate
- 0.0065 per patient-month
- Outperformed the prespecified safety performance goal
- Patients with no false-positive shock alarms
- 94%
- ACE-PAS
- Median daily wear
- 23.1 hours
- ACE-PAS patients
- Patients with at least one VT/VF event
- 2.6%
- Shocked or unshocked events
- Estimated 90-day VT/VF risk
- 3.2%, 2.8%, and 2.5%
- Following myocardial infarction, in ischemic cardiomyopathy, and in nonischemic cardiomyopathy, respectively; patients with LVEF ≤35% meeting primary-prevention criteria
- Projected inappropriate-shock-rate decrease
- Nearly 70%, from 0.0065 to 0.0020 per patient-month
- With the enhanced detection algorithm
Key Terms
wearable cardioverter defibrillators medical
lvef medical
ventricular tachycardia medical
ventricular fibrillation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
KIRKLAND, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced publication of primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, ACE-PAS enrolled 21,612 patients across 35 U.S. states and met both primary safety and effectiveness endpoints. The study demonstrated
“Advances in medical therapy have improved cardiac recovery after a myocardial infarction or a new heart failure diagnosis, but the recovery period can leave patients vulnerable to life-threatening ventricular arrhythmias,” said Jeanne E. Poole, MD, Professor of Medicine at the University of Washington and Principal Investigator. “ACE-PAS confirmed the early risk of ventricular tachycardia and ventricular fibrillation (VT/VF) and demonstrates why WCD protection matters: it provides an opportunity to prevent sudden cardiac death while giving patients time to recover.”
The publication provides a full report of findings first presented as late-breaking science at the American Heart Association Scientific Sessions 2025, along with additional analyses of arrhythmic risk. Key findings include:
100% all-shock conversion- ASSURE WCD successfully converted all 303 analyzable VT/VF shock events with one or more shocks, meeting the primary effectiveness endpoint.
- Primary safety endpoint achieved
- The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety performance goal.
94% of patients experienced no false-positive shock alarms- The low alarm burden supports a better patient experience and helps enable the sustained wear needed for continuous protection.
- 23.1 hours of median daily wear—even beyond 90 days
- Patients wore ASSURE for a median of 23.1 hours per day.
30% continued use beyond 90 days while maintaining the same median daily wear time, highlighting ASSURE’s practicality in real-world, long-term care.
- VT/VF risk persisted beyond the first month
2.6% of patients experienced at least one shocked or unshocked VT/VF event. While55% of episodes occurred during the first month, events continued in subsequent months—reinforcing the need for protection throughout the prescription period.
- Meaningful arrhythmic risk extended across major etiologies
- Among patients with LVEF ≤
35% who met primary-prevention criteria for sudden cardiac death, the estimated risk of experiencing VT/VF within 90 days was3.2% following myocardial infarction,2.8% in ischemic cardiomyopathy and2.5% in nonischemic cardiomyopathy.
- Among patients with LVEF ≤
“Publication of the ACE-PAS results marks an important milestone in advancing the evidence base for wearable defibrillator therapy and monitoring,” said Brian Webster, President and CEO of Kestra Medical Technologies. “Real-world evidence at this scale reinforces confidence in the ASSURE system and strengthens the clinical foundation for protecting patients during recovery. We will continue to build on these insights to give providers more ways to protect at risk patients.”
Drawing on ACE-PAS data, Kestra introduced an enhanced detection algorithm in April 2026 for the ASSURE WCD that further reduces the already low false-positive alarm burden while maintaining VT/VF detection sensitivity. With the enhanced algorithm, the inappropriate shock rate is projected to decrease by nearly
The peer-reviewed publication, “Real-World Performance of a Novel Wearable Cardioverter-Defibrillator System: Primary Results From a National Prospective Post-Approval Registry Study (ACE-PAS),” is available at http://doi.org/10.1111/jce.70556
About ACE-PAS
The ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) was an FDA-mandated, prospective, single-arm post-approval registry evaluating the safety and effectiveness of the ASSURE Wearable Cardioverter Defibrillator in routine clinical use. Funded by Kestra, the study included 21,612 patients fitted between November 2021 and July 2025. Primary endpoints were all-shock VT/VF conversion success and inappropriate-shock incidence, evaluated against prespecified performance goals.
About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. For a discussion of factors that could cause actual results to differ, see Kestra's filings with the U.S. Securities and Exchange Commission. Kestra undertakes no obligation to update any forward-looking statements except as required by law.
- Finch D, et al. Research Square. April 22, 2026. Preprint.
- Poole JE, et al. Circulation. 2025;152:e526–e605.

Media contact Rhiannon Pickus rhiannon.pickus@kestramedical.com Investor contact Neil Bhalodkar neil.bhalodkar@kestramedical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kestra's ACE-PAS study show about ASSURE defibrillator effectiveness and safety?
ASSURE met both primary safety and effectiveness endpoints in ACE-PAS. It converted all 303 analyzable ventricular tachycardia or ventricular fibrillation shock events with one or more shocks. The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety performance goal.
How long did arrhythmia risk persist in Kestra's ACE-PAS study?
VT/VF events continued beyond the first month, although 55% of episodes occurred during that month. Overall, 2.6% of patients experienced at least one shocked or unshocked VT/VF event.